MMEDF - MindMed plans to commence lysergic acid diethylamide assisted therapy for an anxiety disorder next year

MindMed ([[MMEDF]] +33.9%) has completed a pre-IND (Investigational New Drug) meeting with FDA regarding the development of lysergic acid diethylamide ((LSD)) assisted therapy for an anxiety disorder. The company intends to open the IND with the FDA in August 2021, with a Phase 2b trial evaluating experiential doses of LSD in an anxiety disorder.Preliminary data from MindMed's addiction treatment program, named Project Layla evaluating the ibogaine derivative 18-MC, showed that the drug is safe and well tolerated at the doses tested to date, and no Serious Adverse Events have been reported.Based on this data, the company has decided to continue dose escalation in the study to gather higher dosing data. Once that additional data has been reviewed, MindMed will directly thereafter initiate the Phase 2a proof of concept study.

For further details see:

MindMed plans to commence lysergic acid diethylamide assisted therapy for an anxiety disorder next year